PLCG2 and agammaglobulinemia: Autosomal dominant PLCG2 in-frame deletion [8] or missense [p.Ser707Tyr] mutations [9] in the autoinhibitory domain, result in constitutively active or hyperactive phospholipase function, respectively, and lead to diseases characterized by autoimmunity and immunodeficiency, known as PLAID (PLCɣ2-associated antibody deficiency) [8] or APLAID (autoinflammation and PLAID) [9].